GlassScriptPhysician profile
Amanda N Dunham
NPI 1346757127
$2,718.44
in general payments reported to CMS, 2019-2025
18 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.50 · 2022: $412 · 2023: $1,557 · 2024: $435 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253 · Travel and Lodging: $25.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.29 |
| Travel and Lodging | $25.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $910.86 | 2023 | M22 |
| Lilly USA, LLC | $379.90 | 2021-2025 | Mounjaro, Zepbound |
| Galderma Laboratories, L.P. | $293.12 | 2022-2025 | Dysport |
| Abbvie INC. | $137.03 | 2022-2024 | |
| Madrigal Pharmaceuticals | $134.85 | 2025 | Rezdiffra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $122.46 | 2024 | Invega Sustenna |
| Ultragenyx Pharmaceutical INC. | $119.93 | 2023 | Crysvita |
| Merz North America, INC. | $117.25 | 2022-2023 | Xeomin |
| Idorsia Pharmaceuticals US INC | $94.50 | 2023 | Quviviq |
| Musculoskeletal Transplant Foundation INC. | $67.03 | 2023 | |
| Novo Nordisk INC | $56.77 | 2021-2024 | Wegovy |
| Inspire Medical Systems, INC. | $39.35 | 2025 | Inspire |
| Boston Scientific Corporation | $37.81 | 2024 | |
| Ferring Pharmaceuticals INC. | $32.39 | 2024-2025 | Menopur |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $19.28 | 2025 | |
| Astellas Pharma US INC | $18.14 | 2022 | |
| Amgen INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.